{
  "project": "RVCL-S Delivery Outreach",
  "owner": "Steve",
  "created": "2026-02-19",
  "contacts": [
    {
      "id": 1,
      "name": "David Liu",
      "title": "Professor / HHMI Investigator",
      "org": "Broad Institute / Harvard",
      "category": "Academic",
      "expertise": "Prime editing inventor, dual-AAV delivery systems for CNS",
      "relevance": "Invented prime editing itself. Lab actively solving delivery of prime editors to CNS via split-intein AAV. Co-founded Prime Medicine.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://liugroup.us/",
      "intro_path": "Via Dr. Miner (they likely know each other through prime editing work) or Broad Institute directory",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "",
      "outreach_log": []
    },
    {
      "id": 2,
      "name": "Daniel Siegwart",
      "title": "Professor of Biochemistry",
      "org": "UT Southwestern Medical Center",
      "category": "Academic",
      "expertise": "SORT LNP platform — organ-specific lipid nanoparticle targeting including brain",
      "relevance": "Pioneered redirecting LNPs to brain, lung, spleen instead of liver. SORT technology could enable IV-administered brain-targeted delivery of prime editor mRNA.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.utsouthwestern.edu/labs/siegwart/",
      "intro_path": "Direct academic outreach or via UT Southwestern dept of biochemistry",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "",
      "outreach_log": []
    },
    {
      "id": 3,
      "name": "Feng Zhang",
      "title": "Professor / HHMI Investigator",
      "org": "Broad Institute / MIT",
      "category": "Academic",
      "expertise": "Engineered virus-like particles (eVLPs) for gene editor delivery",
      "relevance": "eVLPs deliver pre-formed Cas9/prime editor RNP complexes with tissue targeting. Founded Aera Therapeutics to commercialize. Non-viral, transient delivery.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://zhanglab.bio/",
      "intro_path": "Via Broad Institute or through Aera Therapeutics",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "",
      "outreach_log": []
    },
    {
      "id": 4,
      "name": "Frank Bennett",
      "title": "Chief Scientific Officer (Franchise)",
      "org": "Ionis Pharmaceuticals",
      "category": "Industry",
      "expertise": "ASO therapeutics — CNS delivery, allele-specific knockdown, intrathecal delivery",
      "relevance": "World leader in ASO development. Led Spinraza (SMA), tofersen (ALS). Extensive intrathecal CNS delivery experience. Could develop TREX1-targeting ASO.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.ionispharma.com/",
      "intro_path": "Ionis medical/scientific affairs or warm intro via neurology research community",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "ASO route — complementary to prime editing, not competing",
      "outreach_log": []
    },
    {
      "id": 5,
      "name": "Timothy Miller",
      "title": "Professor of Neurology",
      "org": "Washington University, St. Louis",
      "category": "Academic",
      "expertise": "ASO development for neurodegeneration, tofersen for ALS",
      "relevance": "Bridges neurology clinical practice with ASO development. WashU is also an RVCL research center (Dr. Andria Ford). Could connect RVCL and ASO worlds.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://neurology.wustl.edu/",
      "intro_path": "Via Dr. Miner or Dr. Andria Ford (WashU RVCL connection)",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "",
      "outreach_log": []
    },
    {
      "id": 6,
      "name": "Don Cleveland",
      "title": "Distinguished Professor",
      "org": "UC San Diego",
      "category": "Academic",
      "expertise": "ASO approaches for neurodegenerative diseases, allele-specific knockdown",
      "relevance": "Pioneered ASO strategies for SOD1-ALS. Close Ionis collaborator. Deep expertise in allele-specific CNS ASOs.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://clevelandlab.ucsd.edu/",
      "intro_path": "Direct academic outreach or via Ionis connection",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "",
      "outreach_log": []
    },
    {
      "id": 7,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Prime Medicine",
      "category": "Industry",
      "expertise": "Prime editing therapeutics — commercializing David Liu's technology",
      "relevance": "The company literally built to bring prime editing to patients. Natural partner for Miner lab's RVCL prime editor. CNS programs in development.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.primemedicine.com/",
      "intro_path": "BD inquiry via website, or warm intro through David Liu / Broad network",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "Publicly traded (PRME). Check their pipeline for CNS programs.",
      "outreach_log": []
    },
    {
      "id": 8,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Intellia Therapeutics",
      "category": "Industry",
      "expertise": "In vivo LNP-delivered CRISPR — first FDA-approved in vivo gene editing therapy",
      "relevance": "Most advanced non-viral CRISPR delivery platform. Proven in humans (liver). Expanding to CNS and other organs. LNP expertise directly applicable to RVCL multi-organ delivery.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.intelliatx.com/",
      "intro_path": "Medical affairs or BD inquiry. Could also approach via Jennifer Doudna network.",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "Publicly traded (NTLA). Partner: Novartis.",
      "outreach_log": []
    },
    {
      "id": 9,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Voyager Therapeutics",
      "category": "Industry",
      "expertise": "TRACER AAV capsid platform — brain-penetrant AAV after IV administration",
      "relevance": "Engineered AAV capsids that cross BBB from IV dosing. Partnered with Pfizer and Novartis for CNS delivery. Could carry prime editor payload to brain vasculature.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.voyagertherapeutics.com/",
      "intro_path": "BD inquiry via website. Pfizer/Novartis partnerships may complicate but worth exploring.",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "Publicly traded (VYGR). Focus on neuroscience.",
      "outreach_log": []
    },
    {
      "id": 10,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Passage Bio",
      "category": "Industry",
      "expertise": "CNS-focused gene therapy — AAV delivery to brain",
      "relevance": "Entire company focused on CNS gene therapy delivery. AAV-based platform designed for brain penetration.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.passagebio.com/",
      "intro_path": "BD inquiry via website",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "Publicly traded (PASG). Based in Philadelphia — same city as Miner/UPenn.",
      "outreach_log": []
    },
    {
      "id": 11,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Denali Therapeutics",
      "category": "Industry",
      "expertise": "Transport Vehicle (TV) platform — transferrin receptor-mediated BBB crossing",
      "relevance": "Proven BBB crossing technology using engineered antibodies that hijack transferrin receptor transcytosis. Could be adapted to carry LNPs or gene editing cargo across BBB.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.denalitherapeutics.com/",
      "intro_path": "BD inquiry via website. Partnered with Biogen.",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "Publicly traded (DNLI). BBB transport technology is modular.",
      "outreach_log": []
    },
    {
      "id": 12,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Aera Therapeutics",
      "category": "Industry",
      "expertise": "Engineered virus-like particles (eVLPs) for non-viral gene editor delivery",
      "relevance": "Feng Zhang spinout. Delivers pre-formed RNP complexes — transient editing, tissue-targetable, redosable. Non-viral alternative to AAV.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.aeratx.com/",
      "intro_path": "Via Feng Zhang or direct BD inquiry",
      "status": "Not Contacted",
      "priority": "Medium",
      "notes": "Early stage. Series A funded. Novel platform.",
      "outreach_log": []
    },
    {
      "id": 13,
      "name": "Business Development",
      "title": "Partnerships / BD Team",
      "org": "Ionis Pharmaceuticals",
      "category": "Industry",
      "expertise": "ASO platform — broadest ASO pipeline in the world",
      "relevance": "If pursuing ASO approach alongside prime editing. Proven CNS delivery (intrathecal). Proven allele-specific knockdown. Could develop TREX1 ASO program.",
      "email": "",
      "phone": "",
      "linkedin": "",
      "website": "https://www.ionispharma.com/",
      "intro_path": "Medical/scientific affairs or via Frank Bennett",
      "status": "Not Contacted",
      "priority": "High",
      "notes": "Publicly traded (IONS). Carlsbad, CA. Has rare disease programs.",
      "outreach_log": []
    }
  ],
  "pipeline_stages": ["Not Contacted", "Outreach Sent", "Response Received", "Meeting Scheduled", "Meeting Completed", "In Discussion", "Committed", "Declined"],
  "tags": ["ASO", "Prime Editing", "LNP Delivery", "AAV Delivery", "VLP Delivery", "BBB Crossing", "Academic", "Industry", "CNS", "Retina", "Liver", "Kidney"]
}
